Development and characterization of monoclonal antibodies specific for amylin

Hybridoma

Volumn 15, Issue 5, 1996, Pages 379-386

  Phelps, J L ^a   Blase, E K ^a   Koda, J E ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; MONOCLONAL ANTIBODY; PRAMLINTIDE;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CELL FUSION; DIABETES MELLITUS; GLUCOSE HOMEOSTASIS; HYBRIDOMA; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ANIMALIA;

EID: 0029850418     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1996.15.379     Document Type: Article

References (23)

1. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, and Reid KBM: Purification and characterization of a peptide from amyloidrich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987;84(23):8628-8632.
2. Cooper GJS, Leighton B, Dimitriadu GD, Parry-Billings M, Kowalchuk JM, Rowland K. Rothbard JB, Willis AC, and Reid KBM: Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 1988;85(20):7763-7766.
3. Roberts A, Leighton B, Todd JA, Cockbum D, Schofield PN, Sutton R, Holt S, Boyd Y, Day AJ, Foot EA, Willis AC, Reid KBM, and Cooper GJS: Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci USA 1989;86:9662-9666.
4. Cooper GJS: Amylin compared with calcitonin gene-related peptide. Structure, biology, and relevance to metabolic disease. Endocr Rev 1994;15:163-201.
5. Moore CX, and Cooper GJS: Co-secretion of amylin and insulin from cultured islet B-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun 1991;179(1):1-9.
6. Akimoto K, Nakazato M, Matsukura S, and Hayakawa K: Plasma concentration of islet amyloid polypeptide in healthy children and patients with insulin-dependent diabetes mellitus. Acta Paediat 1993;82(3):310-311.
7. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, and Linarelli LG: Amylin concentrations and glucose control. Lancet 1992;339(8802):1179-1180.
8. Huang HJS, Young AA, Koda JE, Tulp OL, Johnson MJ, and Cooper GJS: Hyperamylinemia, hyperinsulinemia, and insulin resistance in genetically obese LA/N-cp rats. Hypertension 1992;19(1):I101-I109.
9. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H, and Matsukara S: Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1992;15(1): 97-102.
10. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhäusl W, and Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 1994;37(2):188-194.
11. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M, and Nanjo K: Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type2 (non-insulin dependent) diabetic patients. Diabetologia 1991;34(2):129-132.
12. Nakazato M, Asai J, Kangawa K, Matsukura S, and Matsuo H: Establishment of radioimmunoassay for human islet amyloid polypeptide and its tissue content and plasma concentration. Biochem Biophys Res Commun 1989;164(1):394-399.
13. Shiomi K, Nakazato M, Miyazato M, Kangawa K, and Matsuo H: Establishment of hypersensitive radioimmunoassay for islet amyloid polypeptide using antiserum specific for its N-terminal region. Biochem Biophys Res Commun 1992;186(2):1065-1073.
14. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, and Prager R: Basal and stimulated levels of pancreatic amylin indicate its cosecretion with insulin in humans. Diabetologia 1991;34(1):52-54.
15. Butler PC, Chou J, Carter WB, Wang Y-N, Bu B-H, Chang D, Chang J-K, and Rizza RA: Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990;39(6):752-756.
16. Stewart J, and Young J: Solid Phase Peptide Synthesis, 2nd ed. Pierce Chemical Co., Rockford, Ill, 1984.
17. 131I-Iabelled human growth hormone of high specific radioactivity. Biochem J 1963;89:114.
18. Hunter WM, and Greenwood FC: Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature (London) 1962;194:495.
19. Littlefield JW: Selection of hybrids from matings of fibroblasts in vitro and their presumed recombinants. Science 1964;145:709.
20. Kearney JF, Radbrach A, Liesegany B, and Rajewsky K: A new mouse myeloma that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979;123:1548.
21. Gerhard W: In: Monoclonal Antibodies. Kennet R, McKearn TJ, and Bechtol KG (Eds.). Plenum Press, New York, 1980, p. 370.
22. Murasko DM, and Blankenhom EP: Genetic control of neutralizing antibody response to mouse Interferon in rats. J Inter Res 1984;4:435.
23. Percy AJ, Trainor DA, Rittenhouse J and Koda JE: Development of rapid sensitive immunoassays to detect human amylin and amylin-like peptides in plasma. Clin Chem 1996;42(4):576-585.